结直肠癌基因治疗研究进展

doi:j.issn.1009-976X.2014.02.027

摘要/Abstract

摘要： 【摘要】〓结直肠癌是常见的消化道恶性肿瘤,传统治疗以外科手术为主,辅以放、化疗,术后5年生存率仅为50%左右。近年来结直肠癌基因治疗备受人们青睐,且有许多研究成果成功运用于临床。目前对结直肠癌基因治的方法主要有原癌基因治疗、抑癌基因治疗、免疫基因治疗以及多基因联合治疗等。

关键词: 结直肠癌, 基因治疗

Abstract: 【Abstract】〓Colorectal cancer is a common digestive tract cancer. Although the comprehensive treatments with primary surgery integrated with chemiotherapy or radiotherapy, the postoperative 5-year survival rate has not been improved evidently (about 50%). In recent years, gene therapy for colorectal cancer has attracted much attention, nd many research results have been applied in Clinical. Currently, the main methods include proto-oncogenes therapy, tumor suppressor therapy,immunotherapy ,complex gene therapy and so on.

Key words: Colorectal cancer, Gene therapy

中图分类号:

R657.1

钟林李强陈飞邹兆伟郑伟黄宗海. 结直肠癌基因治疗研究进展[J]. 岭南现代临床外科, 2014, 14(02): 207-210.

Zhong Lin, LI Qiang, Chen Fei, Zou Zhaowei, Zheng Wei, Huang Zonghai. Advance in gene-targeted therapy for colorectal cancer[J]. Lingnan Modern Clinics in Surgery, 2014, 14(02): 207-210.

参考文献

[1]. 房静远, 中国结直肠肿瘤筛查、早诊早治和综合预防共识意见(一). 胃肠病学, 2011(11): 第666-675页.
[2]. Guo, S. and K.J. Kemphues, par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell, 1995. 81(4): p. 611-20.
[3]. Fukes F. DNA methylation and histone modification：teaming up to silence genes[J].Curr Opin Genet Dev，2005,15(5):490-495
[4].Yang, J., et al., Adenovirus-mediated siRNA targeting Bcl-xL inhibits proliferation, reduces invasion and enhances radiosensitivity of human colorectal cancer cells. World J Surg Oncol, 2011. 9: p. 117.
[5]. Hur, K., et al., Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut, 2013.
[6]. Noaki, R., et al., Serum p53 antibody is a useful tumor marker of early colorectal cancer. Int Surg, 2010. 95(4): p. 287-92.
[7]. He, Z.Y., et al., Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest, 2011. 29(3): p. 208-13.
[8]. Veganzones-de-Castro, S., et al., p16 gene methylation in colorectal cancer patients with long-term follow-up. Rev Esp Enferm Dig, 2012. 104(3): p. 111-7.
[9]. Nakayama, G., et al., p16INK4a methylation in serum as a follow-up marker for recurrence of colorectal cancer. Anticancer Res, 2011. 31(5): p. 1643-6.
[10]. Parney, I.F. and L.J. Chang, Cancer immunogene therapy: a review. J Biomed Sci, 2003. 10(1): p. 37-43.
[11]. He, X., et al., Inhibition of colon tumor growth by IL-15 immunogene therapy. Mol Med Rep, 2012. 5(1): p. 96-102.
[12]. Parkhurst, M.R., et al., T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther, 2011. 19(3): p. 620-6.
[13]. Ortiz, R., et al., 5-Fluorouracil-loaded poly(epsilon-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. Int J Nanomedicine, 2012. 7: p. 95-107.
[14]. 刘志毅等, pAdKDR/CD/TK自杀基因系统对大肠癌SW480细胞体外杀伤作用的实验研究. 中国临床研究, 2011(02): 第91-95页.
[15]. 李强等, 腺病毒介导的KDR-CDglyTK系统在治疗胃癌中的旁观者效应机制. 世界华人消化杂志, 2012(09): 第749-753页.
[16]. Zhao, Z., et al., Vascular endothelial growth factor (VEGF) gene polymorphisms and colorectal cancer: a meta-analysis of epidemiologic studies. Genet Test Mol Biomarkers, 2012. 16(12): p. 1390-4.
[17]. Messner, I., et al., KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol, 2013. 139(2): p. 201-9.
[18]. Shen, K., et al., Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem, 2012. 113(6): p. 2086-97.
[19]. Rahman, M., et al., Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia, 2012. 14(7): p. 624-33.
[20]. 姚晓军等, Ad-VEGF-GFP-CD/TK双自杀基因系统对大肠癌的生长抑制作用及微环境中细胞因子活性的影响. 南方医科大学学报, 2010(02): 第260-262页.
[21]. Kameshima, H., et al., Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci, 2011. 102(6): p. 1181-7.